This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEAB20I9_M.jpg
Merck&Co announced earnings per share of $1.5 on revenue of $12.06B. Analysts polled by Investing.com anticipated EPS of $1.34 on revenue of $11.48B. That with comparison to EPS of $1.22 on revenue of $10.82B in the same period a year before. Merck&Co had reported EPS of $1.16 on revenue of $11.87B in the previous quarter. Analysts are expecting EPS of $1.31 and revenue of $11.75B in the upcoming quarter.
Merck&Co shares are down 7% from the beginning of the year , still down 9.35% from its 52 week high of $92.64 set on December 20, 2019. They are outperforming the S&P 500 which is down 11.29% year to date.
Merck&Co’s report follows an earnings beat by J&J on April 14, who reported EPS of $2.3 on revenue of $20.69B, compared to forecasts EPS of $2.02 on revenue of $19.73B.
Novartis ADR had beat expectations on Tuesday with first quarter EPS of $1.56 on revenue of $12.28B, compared to forecast for EPS of $1.37 on revenue of $11.99B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
